119例英夫利西单抗不良反应的文献分析

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (4): 229-232.

• 安全性评估与合理用药 • 上一篇下一篇

119例英夫利西单抗不良反应的文献分析

李峰,晋红中

北京协和医院皮肤科,北京 100730

收稿日期:2016-03-06 修回日期:2016-06-30 出版日期:2016-04-20 发布日期:2016-06-30
通讯作者: 晋红中,男,博士,主任医师·博导,皮肤性病学。E-mail:jinhongzhong@263.net
作者简介:李峰,女,博士,主治医师,皮肤性病学。

Literature Analysis of 119 Cases of Adverse Drug Reactions Induced by Infliximab

LI Feng, JIN Hong-zhong

Department of Dermatology, Peking Union Medical College Hospital,Beijing 100730, China

Received:2016-03-06 Revised:2016-06-30 Online:2016-04-20 Published:2016-06-30

摘要/Abstract

摘要： 目的探讨英夫利西单抗不良反应的特点,为临床安全用药提供参考。方法在中国期刊全文数据库和万方数据库中,检索2008~2015年之间公开发表的关于英夫利西单抗不良反应的文献,对筛选出的119例病例进行回顾性分析。结果原患疾病主要包括类风湿性关节炎、强直性脊柱炎、溃疡性结肠炎、克罗恩病、银屑病/银屑病性关节炎、幼年特发性关节炎。不良反应最易发生于第3~4次输液期间。输液反应最常见,常累及的系统-器官主要包括皮肤黏膜（29.49%）、呼吸系统（30.77%）、消化系统（14.10%）、心血管系统（10.26%）等。多数药品不良反应预后良好。结论英夫利西单抗药品不良反应累及多个系统-器官,须提高警惕,注意监测,及时处理。

关键词: 英夫利西单抗, 药品不良反应, 文献分析

Abstract: Objective To explore the general characteristics of adverse drug reactions induced by infliximab, and provide reference for safe and rational use of infliximab. Methods The articles about infliximab adverse reactions published from 2008 to 2015 in Wanfang and CNKI databases were searched, and the 119 cases documented by the articles were reviewed retrospectively. Results Primary diseases include rheumatoid arthritis, ankylosing spondylitis, ulcerative colonitis, Crohn’s disease, psoriasis, and juvenile idiopathic arthritis. Most adverse reactions occurred during the 3rd and 4th treatments. Infusion reactions were the most common. Skin, respiratory system, digestive system and coronary vascular system were often involved. Prognosis of most adverse reactions were good. Conclusion Adverse drug reactions induced by infliximab involve multiple systems and organs. Vigillance, surveillance and quick management are required.

Key words: infliximab, adverse drug reactions, literature analysis

中图分类号:

R994.11

李峰,晋红中. 119例英夫利西单抗不良反应的文献分析[J]. 中国药物警戒, 2016, 13(4): 229-232.

LI Feng, JIN Hong-zhong. Literature Analysis of 119 Cases of Adverse Drug Reactions Induced by Infliximab[J]. Chinese Journal of Pharmacovigilance, 2016, 13(4): 229-232.

参考文献

[1] 姚新飞,许素清,谢麒麟. 不同输注方法对英夫利西单抗不良反应的影响[J]. 护理学杂志,2013,28(8):17-19.
[2] Fukuyo S, Saito K, Yamaoka K, et al. Efficacy and safety of reducing duration of infliximab infusion[J]. Mod Rheumatol, 2014,24(2):275-280.
[3] 陈国强,郭冬梅,张红卫,等.英夫利西单抗注射安全性的临床观察[J].实用医学杂志,2010,26(13):2415-2416.
[4] Tyler L N, Harville T O, Blackall D P. Multiple alloantibodies after transfusion in an infant treated with infliximab[J]. N Engl J Med,2007,357(20): 2092-2093;
[5] Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgEantibodies and induction of infusion-related severe anaphylactic reactions[J]. Allergy,2010,65(5):657-661.
[6] 杨世春.临床输液反应相关因素探讨及预防[J].中国医药指南,2011,9(20):299-300.
[7] Dixon W G, Hyrich K L, Watson K D, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3):522–528.
[8] Navarra S V, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia[J]. Int J Rheum Dis,2014,17(3):291-298.
[9] Solovic I, Sester M, Gomez-Reino J J, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement[J]. Eur Respir J,2010,36(5): 1185-1206.
[10] 中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志,2014,47（3）:213-215.
[11] 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J].中华风湿病学杂志,2013,17（8）:508-512.
[12] Bjrnsson E S, Gunnarsson B I, Grndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol,2015,13(3): 602-608.
[13] Rossi R E, Parisi I, Despott E J, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management[J]. World J Gastroenterol,2014,20(46):17352-17359.
[14] Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B
reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis[J]. Gut,2004,53(9):1363–1365.
[15] Castro K R, Aikawa N E, Saad C G, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients[J]. Clin DevImmunol,2011,2011(2):352686.
[16] Koutroubakis I E, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease[J].Eur J Gastroenterol Hepatol,2009,21(3):283–288.
[17] 方霖楷,潘云峰,黄建林,等. 类风湿关节炎伴 HBV 携带患者接受英夫利昔单抗治疗的肝脏安全性观察[J]. 风湿病与关节炎,2014,3（2）:27-29.
[18] Phelan C, Wooltorton E. Infliximab and serious hematologic events[J].CMAJ,2004, 171(9):1045.
[19] 胡扬,王兰,张波,等. 英夫利西单抗诱发再生障碍性贫血[J]药物不良反应杂志,2012,14（6）:382-384.
[20] Mocciaro F, Russo G, Di Mitri R, et al. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn’s disease[J]. Inflamm Bowel Dis,2013, 19(4):E52-E53.

119例英夫利西单抗不良反应的文献分析

Literature Analysis of 119 Cases of Adverse Drug Reactions Induced by Infliximab

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.